Cancer: Breast Disorders: Merck Manual Home Edition Search Recent Searches Index Sections A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Accidents and Injuries Blood Disorders Bone, Joint, and Muscle Disorders Brain, Spinal Cord, and Nerve Disorders Cancer Children's Health Issues Digestive Disorders Disorders of Nutrition and Metabolism Drugs Ear, Nose, and Throat Disorders Eye Disorders Fundamentals Heart and Blood Vessel...
Fulvestrant - [Medication] - Quest Diagnostics Patient Health Library Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Fulvestrant - [Medication] - Quest Diagnostics Patient Health Library Fulvestrant - [Medication] - Quest Diagnostics Patient Health Library Cancer, Breast cancer, Breast Cancers, breast malignant neoplasm, drug treatment of disease, faslodex, ...
APPROVAL GRANTED FOR FASLODEX (FULVESTRANT) IN EU Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2004 - - function managePressContacts() { window.navigate("ncm.aspx?node=press");...
POSITIVE OPINION GIVEN ON APPROVABILITY OF FASLODEX (FULVESTRANT) IN EUROPEAN UNION Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2003 - - function managePressContacts() { window.navigate("ncm.aspx?node=press");...
AstraZeneca International - pharmaceutical company, prescription drugs, medicine manufacturers Skip to content Home Media Investors Careers Products Licensing Research Responsibility About us Contact us - - Oncology Over 12 million people are diagnosed with cancer each year, and it is predicted to be the leading cause of death in the US by 2005.
AstraZeneca News - press release archive - pharmaceutical news - 2003 Skip to content Home Media Press releases - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 Corporate reports Facts, products, pipeline Image library Events calendar Media contacts Investors Careers Products Licensing Research Responsibility About us Contact us Home - - Media - - Press releases - -2003 - - Press release archive 2003 23 December 2003 EXANTAa„¢ ...
BioPortfolio Limited Cell Signalling Pathways Section Summary 1 Executive Summary 2 Introduction Membrane Receptor Pathways Mitogen-Activated Protein Kinase Pathways G-Protein Coupled Receptors PI3K/Akt Signalling Jak/STAT Signalling NF-kB Signalling Insulin Signalling B Cells and T Cells Nuclear Receptors Nuclear Receptor Structure Nuclear Receptors as Pharmaceutical Targets 3 Cancer Market for Novel...
Database F F - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products.
http://www.fda.gov/cder/orange/appendix_a.txt 400, ERYTHROMYCIN ETHYLSUCCINATE E.E.S., ERYTHROMYCIN ETHYLSUCCINATE EC-NAPROSYN, NAPROXEN ECONAZOLE NITRATE, ECONAZOLE NITRATE ECONOCHLOR, CHLORAMPHENICOL ECONOPRED PLUS, PREDNISOLONE ACETATE ECONOPRED, PREDNISOLONE ACETATE EDECRIN, ETHACRYNATE SODIUM EDECRIN, ETHACRYNIC ACID EDETATE DISODIUM, EDETATE DISODIUM EDEX, ALPROSTADIL EDROPHONIUM CHLORIDE PRESERVATIVE FREE, EDROPHONIUM...
C:\Data\My Documents\NDAs\21344\SE8-001\Letters\ap.ltr.doc The molecular formula is C32H47F5O3S and its structural formula is: OH O H (CH 2 ) 9 SO( CH 2 ) 3 CF 2 CF 3 Fulvestrant is a white powder with a molecular weight of 606.77Fulvestrant downregulates the ER protein in human breast cancer cellsFulvestrant resistant breast tumor xenografts may also be cross- resistant to tamoxifenFulvestrant showed no...
author: Amy Baird
C:\Data\My Documents\NDAs\21344\SE8-001\Letters\ap.ltr.doc page 11
author: Amy Baird
C:\Data\My Documents\NDAs\21344\SE8-001\Letters\ap.ltr.doc page 8
author: Amy Baird
C:\Data\My Documents\NDAs\21344\SE8-001\Letters\ap.ltr.doc page 7
author: Amy Baird
C:\Data\My Documents\NDAs\21344\SE8-001\Letters\ap.ltr.doc page 4
author: Amy Baird
C:\Data\My Documents\NDAs\21344\SE8-001\Letters\ap.ltr.doc page 3
author: Amy Baird
C:\Data\My Documents\NDAs\21344\SE8-001\Letters\ap.ltr.doc page 1
author: Amy Baird
../2002/21-344_Faslodex_Fulvestrant Food and Drug Administration • Center for Drug Evaluation and Research Title Search Faslodex (Fulvestrant) Injection Company:--AstraZeneca Pharmaceuticals Application No.:--21-344 Approval Date:-4/25/2002 Approval Letter(s) - Printed Labeling - Medical Review(s)- Part 1 - Part 2 - Part 3 - Chemistry Review(s) - Pharmacology Review(s)- Part 1 - Part 2 - Part 3 -...
author: USERNAME
CDER 2002 Report to the Nation; Drug Review Food and Drug Administration • Center for Drug Evaluation and Research About CDER - Report Search CDER Report to the Nation: 2002 Table of Contents Adobe Acrobat version of this document 1 Drug Review Index Mission Highlights New Drug Review List of priority new drugs List of new molecular entities List of orphan new drugs New Drug Review Statistics Priority new drug statistics...
author: OLIVERN
NMEs Approved in CY 2002 NMEs Approved in Calendar Year 2002 - NDA Number Generic Name Trade Name Dosage Form Applicant *Classification Approval Date 21-232 Nitisinone Orfadin Capsule Swedish Orphan -- 1PV 01-18-2002 21-286 Olmesartan Medoxomil Benicar Tablet Sankyo- 1S 04-25-2002 21-344 Fulvestrant Faslodex Injection AstraZeneca 1S 04-25-2002 21-272 Treprostinil Sodium Remodulin Injection United...
author: Susan Daugherty
Prescription and OTC Drug Product List 4/2002 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE CAPSULE; ORAL ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE -A- AB VINTAGE PHARMS 325MG;50MG;40MG;30MG N75929 001 APR 22, 2002 APR NEWA ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE;...
Future Drugs Current Issue Back Issues Drug Profiles Sample Articles Event Listing Links Contact Details Editorial Board Aims & Scope Author Info Search - Advanced Search Expert Review of Anticancer Therapy Drug Profile ...
Future Drugs Current Issue Back Issues Drug Profiles Sample Articles Event Listing Links Contact Details Editorial Board Aims & Scope Author Info Search - Advanced Search Expert Review of Anticancer Therapy Drug Profile ...
Future Drugs Current Issue Back Issues Drug Profiles Sample Articles Event Listing Links Contact Details Editorial Board Aims & Scope Author Info Search - Advanced Search - Expert Review of Anticancer Therapy 2(2),2002 ...
Future Drugs Current Issue Back Issues Drug Profiles Sample Articles Event Listing Links Contact Details Editorial Board Aims & Scope Author Info Search - Advanced Search - Expert Review of Anticancer Therapy ...
Document Information Page The molecular formula is C32H47F5O3S and its structural formula is: OH O H (CH 2 ) 9 SO( CH 2 ) 3 CF 2 CF 3 Fulvestrant is a white powder with a molecular weight of 606.77Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to that of estradiolFulvestrant resistant breast tumor...
author: CDER USER
